Biotech companies face unique challenges in developing increasingly complex biologic therapies. How can early de-risking, a smart chemistry, manufacturing and controls (CMC) strategy, and the right contract development and manufacturing organisation (CDMO) partnership help accelerate progress to the clinic without compromising quality, regulatory readiness, or long-term success?
In this BIO-Europe Spring Supplement article, Lonza experts Megan Mason and Alice Harrison explore how these challenges can be addressed earlier in development through more informed candidate selection and optimization, a pragmatic CMC approach, and development choices that help teams make better decisions and stay on track to IND.
What you'll gain from this article:
- Understand where early decisions can create, or prevent, delays across developability, expression systems, formulation, and CMC strategy.
- Learn how to identify and address molecular liabilities earlier using approaches such as in silico assessment, targeted optimization, and tailored process development.
- See how the right early strategy and partner can help you stay on track to IND while reducing rework, protecting timelines, and reinforcing investor confidence.
